ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade
This study is looking at whether a shorter, 6-month course of targeted therapy works just as well as the standard 12-month course for early-stage HER2-positive breast cancer. Researchers want to see if patients who have already had a great response to treatment before surgery can safely receive fewer months of medication.
This study is currently recruiting adults with early-stage HER2-positive breast cancer who had no active cancer remaining after their initial treatment before surgery. You might be able to join if you meet specific medical and tumor requirements set by the study team.
Each participant's group is chosen at random by chance, not by you or your doctor. One group receives 12 months of targeted therapy, while the other group receives 6 months of targeted therapy. You will also experience regular heart scans, imaging tests, and health questionnaires.
This study is currently recruiting participants at about 600 sites in the United States and Puerto Rico. The study team is ready to take new participants who qualify.
- 1Comparing a 6-month and a 12-month course of targeted therapy
- 2Study groups are assigned by chance
- 3Currently recruiting at about 600 locations in the United States and Puerto Rico
Related videos
2Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.